Literature DB >> 25633482

Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.

Y Terasawa1, T Hotani1, Y Katayama1, M Tachibana1, H Mizuguchi2, F Sakurai3.   

Abstract

Reovirus has gained much attention as an anticancer agent; however, the mechanism of the tumor cell-specific replication of reovirus is not fully understood. Although Ras activation is known to be crucial for tumor cell-specific replication of reovirus, it remains controversial which cellular factors are required for the reovirus-mediated tumor cell killing. In this study, we systematically investigated which cellular factors determined the efficiencies of reovirus-mediated tumor cell killing in various human cultured cell lines. The efficiency of reovirus-mediated cell killing varied widely among the cell lines. Junction adhesion molecule-A, a reovirus receptor, was highly expressed in almost all cell lines examined. Ras activation levels were largely different between the cell lines; however, there were no apparent correlations among the reovirus-mediated cell killing efficiencies and Ras activation status. On the other hand, activity levels of the cysteine proteases cathepsins B and L, which are crucial for proteolytic disassembly of the outer capsid proteins of reovirus, showed a tendency to be correlated with the efficiency of reovirus-mediated cell killing. These results indicate that the activity of cathepsins B and L is the most suitable as a biomarker for the efficacy of reovirus-mediated oncolysis among the factors examined in this study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633482     DOI: 10.1038/cgt.2015.4

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  41 in total

1.  Reovirus infection of cancer cells is not due to activated Ras pathway.

Authors:  L Song; T Ohnuma; I H Gelman; J F Holland
Journal:  Cancer Gene Ther       Date:  2008-10-24       Impact factor: 5.987

2.  Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C.

Authors:  S Coulibaly; H Schwihla; M Abrahamson; A Albini; C Cerni; J L Clark; K M Ng; N Katunuma; O Schlappack; J Glössl; L Mach
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

3.  Transcription in vitro by reovirus-associated ribonucleic acid-dependent polymerase.

Authors:  A K Banerjee; A J Shatkin
Journal:  J Virol       Date:  1970-07       Impact factor: 5.103

4.  The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.

Authors:  J E Strong; P W Lee
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.

Authors:  Miao Yin; Johanna Soikkeli; Tiina Jahkola; Susanna Virolainen; Olli Saksela; Erkki Hölttä
Journal:  Am J Pathol       Date:  2012-10-10       Impact factor: 4.307

6.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  Cathepsin S supports acid-independent infection by some reoviruses.

Authors:  Joseph W Golden; Jessica A Bahe; William T Lucas; Max L Nibert; Leslie A Schiff
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

8.  The preferential cytotoxicity of reovirus for certain transformed cell lines.

Authors:  G Hashiro; P C Loh; J T Yau
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

9.  Reovirus therapy of tumors with activated Ras pathway.

Authors:  M C Coffey; J E Strong; P A Forsyth; P W Lee
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

10.  Neutrophil elastase, an acid-independent serine protease, facilitates reovirus uncoating and infection in U937 promonocyte cells.

Authors:  Joseph W Golden; Leslie A Schiff
Journal:  Virol J       Date:  2005-05-31       Impact factor: 4.099

View more
  9 in total

1.  Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Authors:  Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.

Authors:  Michael A Giacomantonio; Andra M Sterea; Youra Kim; Joao A Paulo; Derek R Clements; Barry E Kennedy; Moamen J Bydoun; Ge Shi; David M Waisman; Steven P Gygi; Carman A Giacomantonio; J Patrick Murphy; Shashi Gujar
Journal:  J Proteome Res       Date:  2020-01-17       Impact factor: 4.466

Review 3.  Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-02-24

4.  Comparative proteomic analyses demonstrate enhanced interferon and STAT-1 activation in reovirus T3D-infected HeLa cells.

Authors:  Peyman Ezzati; Krysten Komher; Giulia Severini; Kevin M Coombs
Journal:  Front Cell Infect Microbiol       Date:  2015-04-07       Impact factor: 5.293

5.  Proteolytic disassembly of viral outer capsid proteins is crucial for reovirus-mediated type-I interferon induction in both reovirus-susceptible and reovirus-refractory tumor cells.

Authors:  Yuki Katayama; Yuichi Terasawa; Masashi Tachibana; Hiroyuki Mizuguchi; Fuminori Sakurai
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

Review 6.  Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.

Authors:  Tarryn Bourhill; Yoshinori Mori; Derrick E Rancourt; Maya Shmulevitz; Randal N Johnston
Journal:  Viruses       Date:  2018-08-11       Impact factor: 5.048

Review 7.  Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.

Authors:  Adil Mohamed; Randal N Johnston; Maya Shmulevitz
Journal:  Viruses       Date:  2015-12-01       Impact factor: 5.048

Review 8.  Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Authors:  Samantha Turnbull; Emma J West; Karen J Scott; Elizabeth Appleton; Alan Melcher; Christy Ralph
Journal:  Viruses       Date:  2015-12-02       Impact factor: 5.048

9.  Cathepsin B-Responsive Liposomes for Controlled Anticancer Drug Delivery in Hep G2 Cells.

Authors:  Seulgi Lee; Su Jeong Song; Jeil Lee; Tai Hwan Ha; Joon Sig Choi
Journal:  Pharmaceutics       Date:  2020-09-14       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.